Aadi Biosciences Inc (AADI)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Neil P. Desai
Employees:
50
17383 SUNSET AVENUE, SUITE A250, PACIFIC PALISADES, CA, 90272
424-473-8055

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.

Data derived from most recent annual or quarterly report
Market Cap 615.336 Million Shares Outstanding47.37 Million Avg 30-day Volume 73.076 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.18
Price to Revenue27.3486 Debt to Equity0.0 EBITDA-62.97 Million
Price to Book Value1.7772 Operating Margin-574.702 Enterprise Value117.526 Million
Current Ratio10.612 EPS Growth0.785 Quick Ratio10.355
1 Yr BETA 1.0568 52-week High/Low 21.15 / 11.0 Profit Margin-569.5696
Operating Cash Flow Growth-282.5019 Altman Z-Score5.8951 Free Cash Flow to Firm -35.002 Million
Earnings Report2023-03-16

Are you looking for this stock instead?

View SEC Filings from AADI instead.

View recent insider trading info

Funds Holding AADI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AADI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-23:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2022-12-07:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-28:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2022-06-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DELANEY BRENDAN SEE REMARKS

    • Officer
    • Director
    150,000 2023-01-03 3

    DESAI NEIL EXECUTIVE CHAIRMAN

    • Officer
    • Director
    • 10% Owner
    150,000 2023-01-03 3

    CASTELEIN CALEY

    • Director
    519,692 2022-09-26 2

    DALAL ANUPAM

    • Director
    1,850,532 2022-09-26 2

    GIACOBELLO SCOTT M. CHIEF FINANCIAL OFFICER

    • Officer
    20,000 2022-09-26 2

    AGHAZADEH BEHZAD

    AVORO CAPITAL ADVISORS LLC

    AVORO VENTURES LLC

    • Director
    • 10% Owner
    • SEE REMARKSSEE REMARKSSEE REMARKS
    3,471,752 2022-09-22 2

    MAROUN RICHARD E

    • Director
    18,573 2022-06-15 1

    HEHENBERGER KARIN M.

    • Director
    18,573 2022-06-15 1

    REEVE EMMA

    • Director
    18,573 2022-06-15 1

    ITRI LORETTTA M CHIEF MEDICAL OFFICER

    • Officer
    67,300 2022-04-01 1

    THIBAULT LANCE E CHIEF FINANCIAL OFFICER

    • Officer
    0 2021-08-26 0

    PRELACK STEVEN

    • Director
    24,485 2021-06-30 0

    COHEN CHERYL

    • Director
    16,160 2021-06-30 0

    DUGEL PRAVIN

    • Director
    12,568 2021-06-30 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    • 10% Owner
    5,193,946 2020-12-08 0

    PETERS KEVIN G. SEE REMARKS

    • Officer
    0 2020-03-16 0

    GARDNER JOSEPH H. PRESIDENT

    • Officer
    • Director
    0 2020-03-16 0

    MAREK REGINA VICE PRESIDENT OF FINANCE

    • Officer
    0 2020-03-16 0

    SATTER MUNEER A

    • Director
    • 10% Owner
    0 2019-06-18 0

    KHUONG CHAU QUANG

    • Director
    • 10% Owner
    0 2019-06-18 0

    HOFFMAN STEPHEN J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    0 2019-05-14 0

    ROGERS MICHAEL W SEE REMARKS

    • Officer
    0 2019-05-14 0

    NOVARTIS BIOVENTURES LTD

    NOVARTIS AG

    • 10% Owner
    No longer subject to file 2019-04-25 0

    PAKOLA STEVE CHIEF MEDICAL OFFICER

    • Officer
    0 2019-02-15 0

    DESAI DHAVAL CHIEF STRATEGY OFFICER

    • Officer
    75,342 2018-05-09 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    ISALY SAMUEL D

    • Director
    • 10% Owner
    3,653,451 2017-03-15 0

    WEISS PAUL M

    • Director
    1,303,865 2017-03-15 0

    MURPHY JAMES B SEE REMARKS

    • Officer
    0 2017-03-15 0

    PAPPAJOHN JOHN PRESIDENT

    • Officer
    • Director
    • 10% Owner
    2,000,000 2008-04-01 0

    KINLEY MATTHEW P SECRETARY, CFO

    • Officer
    • Director
    • 10% Owner
    2,000,000 2008-04-01 0

    VASSILIOU ARGYRIS

    • 10% Owner
    1,000,000 2008-04-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DESAI NEIL - Director - Officer - > 10% Owner EXECUTIVE CHAIRMAN

    2023-01-04 16:05:55 -0500 2023-01-03 A 150,000 a 150,000 direct

    DELANEY BRENDAN - Director - Officer SEE REMARKS

    2023-01-04 16:08:45 -0500 2023-01-03 A 150,000 a 150,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AADI BIOSCIENCE INC AADI 2023-01-26 22:15:03 UTC 2.3673 1.9527 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 21:45:03 UTC 2.3673 1.9527 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 21:15:04 UTC 2.3673 1.9527 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 20:45:03 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 20:15:04 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 19:45:03 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 19:15:04 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 18:45:03 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 18:15:04 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 17:45:04 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 17:15:04 UTC 2.3476 1.9724 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 16:45:03 UTC 2.4758 1.8442 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 16:15:04 UTC 2.4758 1.8442 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 15:45:03 UTC 2.4758 1.8442 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 15:15:04 UTC 2.4758 1.8442 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 14:45:04 UTC 2.7536 1.5664 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 14:15:03 UTC 2.7536 1.5664 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 13:45:03 UTC 2.7536 1.5664 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 13:15:04 UTC 2.7536 1.5664 100000
    AADI BIOSCIENCE INC AADI 2023-01-26 12:45:04 UTC 2.7536 1.5664 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AADI -600.0 shares, $-8478.0 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments